Extracellular vesicles (EVs) hold great promise as therapeutic modalities due to their
endogenous characteristics, however, further bioengineering refinement is required to …

Cells have emerged as a promising new form of drug delivery carriers owing to their
distinguished advantages such as naturally bypassing immune recognition, intrinsic …

Conventional thrombolytic drugs for vascular blockage such as tissue plasminogen activator
(tPA) are challenged by the low bioavailability, off-target side effects and limited penetration …

Targeted drug delivery to disease-associated activated neutrophils can provide novel
therapeutic opportunities while avoiding systemic effects on immune functions. We created a …

Poly (lactic‐co‐glycolic acid)(PLGA) nanoparticles (NPs) are commonly used for drug
delivery because of their favored biocompatibility and suitability for sustained and controlled …

Extracellular vesicles (EVs) are well-established mediators of cell-to-cell communication.
EVs can be released by every cell type and they can be classified into three major groups …

Rapid cut‐off of blood supply in diseases involving thrombosis is a major cause of morbidity
and mortality worldwide. However, the current thrombolysis strategies offer limited results …

Ischemic stroke is a cerebrovascular disease normally caused by interrupted blood supply to
the brain. Ischemia would initiate the cascade reaction consisted of multiple biochemical …

Ischemic stroke leads to high disability and mortality. The limited delivery efficiency of most
therapeutic substances is a major challenge for effective treatment of ischemic stroke …

Cardiovascular diseases have become the major killers in today's world, among which
coronary artery diseases (CADs) make the greatest contributions to morbidity and mortality …